A blend name is a SKU, not a formula
GLOW. KLOW. Wolverine. They read like formulations: a fixed recipe, the way "aspirin 325 mg" is a fixed recipe. They are not. They are names suppliers print on vials, and the composition behind the name changes depending on who printed it.
One supplier says it outright about KLOW: "The name is an acronym drawn from its components, and it is a supplier SKU identifier rather than a designation with any regulatory or clinical meaning."
That is the whole lesson, and the arithmetic below is why it matters more than it sounds.
The same name, two different doses
Three affiliate dosing sites describe GLOW as a 70 mg vial containing GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg.
A vendor called PSPeptides sells GLOW as a 70 mg vial containing GHK-Cu 30 mg / BPC-157 20 mg / TB-500 20 mg. Same name. Same total milligrams.
Work out what that means for a person who runs out and reorders from a different shop. Their BPC-157 dose doubles. Their GHK-Cu dose falls by 40%. Nothing on either label tells them, nothing in the product name changes, and if a side effect appears in week three they will look for a cause in their training, their sleep or their diet, because as far as they can see, the vial is the same vial.
That is the single most important safety fact in the blend landscape, and it is not on any product page.
Why "seven sources agree" is not corroboration
Seven or eight vendor and affiliate pages describe the same composition for KLOW. That sounds like independent confirmation. It is not.
It is one content genre repeating itself: affiliate pages copy each other, and one of those "sources" is a vendor's own paid press release. Independent corroboration means two parties who could have disagreed and did not. Copies of a copy are one source with a bigger footprint.
The acronym does not decode
For GLOW, only one letter is ever explained by any source: G = GHK-Cu, named as the dominant component. L, O and W are never expanded anywhere. For KLOW, nobody expands L, O or W either.
If you find yourself reasoning from the letters to the contents, stop. The letters were chosen for a product, not derived from a formula.
What to do instead
Read the COA, not the name. The certificate of analysis for your specific batch is the only document that states what is in your vial. It is the same document Module 2 has been teaching you to read: identity by mass spectrometry, purity by HPLC, endotoxin below 0.5 EU/mg.
Write down the per-compound milligrams before you reconstitute. Then derive your per-compound doses from that, not from a protocol written against somebody else's vial.
Re-check on every reorder, and especially on every vendor change. This is the one moment where the risk concentrates.
Treat a blend as the number of compounds it contains, not as one product. A four-compound vial is four compounds by every measure that matters: four unknowns, four sets of interactions, and no ability to stop one of them without stopping all four.
And one thing to disregard
You will find a rule circulating that tells you exactly which colour a reconstituted copper-peptide blend should be, exactly which colour means it has degraded and must be discarded, and that a pH conflict between the components makes that degradation inevitable.
It is concrete, actionable, and completely unsourced, which is why we do not reproduce the thresholds here. No stability study exists for these peptides in shared solution. Nobody has measured a colour-change threshold against an assay, and there is no analytical chemistry behind the pH story. A discard rule with no data behind it is worse than no rule, because it tells you a vial is fine right up until the moment it tells you it is not, and you will believe both.
The honest position on a blend's stability is that nobody knows. Store it as you would any reconstituted peptide, respect the beyond-use window, and treat visible cloudiness or particulate matter as a reason to stop, the same standard you would apply to any injectable, arrived at without inventing a colour chart.